The Progression From Treatment With Ruxolitna

Progression from therapy with the Ruxolitna, which is typical for choice for control of the spleen and symptoms, may manifest itself in different ways. NCC and GALIS already lists LUSPATASET as a possibility of prescribing to malphabrodis for people who suffer from anemia. The second problem is progressive in a sling. Here, again, you would add rather than replace. You would add cytoreduction therapy, but this is the prime example where we need new drugs.